Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag for Sarcoidosis-Associated Pulmonary Hypertension (SAPH)
NCT03942211Phase 2Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in Sarcoidosis-associated pulmonary hypertension (SAPH) comparing Selexipag with Placebo (2 arms). Primary endpoint: Pulmonary Vascular Resistance at Week 26. Started Feb 2021; status: terminated.
02
Drugs
selexipag
03
Conditions
Sarcoidosis-associated pulmonary hypertension (SAPH)
Beyond the preview
Go deeper on NCT03942211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03942211.